<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776878</url>
  </required_header>
  <id_info>
    <org_study_id>DRAMA GIST</org_study_id>
    <nct_id>NCT02776878</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST</brief_title>
  <official_title>A Prospective, Single-arm, Multi-center Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in RefrActory MetAstatic Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dasatinib is effective and safe in the&#xD;
      treatment of refractory metastatic gastrointestinal stromal tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survive, calculated from registration until progression or death</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, overall survival will be calculated from registration until death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions according to NCI CTCAE v4.0</measure>
    <time_frame>2 years, Tolerability will be assessed based on the frequency and severity of Adverse Drug Reactions (ADR) coded according to NCI CTCAE v4.0.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed recurrent/metastatic gastrointestinal stromal tumor (GIST).&#xD;
             Immunohistochemically, the detection KIT and/or DOG-1 are/is positive&#xD;
&#xD;
          -  Patients must have measurable disease meeting the requirement of RECIST 1.1&#xD;
&#xD;
          -  Received the gene mutation detection of c - kit/PDGFRA&#xD;
&#xD;
          -  Subjects with mutation in exon 11, in exon 9 and wild type c-kit/PDGFRA have failed to&#xD;
             imatinib and sunitinib&#xD;
&#xD;
          -  Subjects with primary mutation in exon 17 or 18 have failed to imatinib&#xD;
&#xD;
          -  Subjects with primary mutation in exon 11 and secondary mutation in exon 17 or 18 have&#xD;
             failed to imatinib&#xD;
&#xD;
          -  Subjects with mutation in exon 18 of PDGFRA,have received TKI or not&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status = 0-2&#xD;
&#xD;
          -  Expected OS ≥3 months&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Subject will comply with the study procedures and therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Local or metastatic GIST is resectable&#xD;
&#xD;
          -  Unable to receive the gene mutation detection of c-kit&#xD;
             (c-kitproto-oncogeneprotein)/PDGFRA&#xD;
&#xD;
          -  AST and/or ALT &gt; 2.5 times ULN, or Bilirubin &gt;1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Neutrophil count &lt; 1.5 x 10^9/L, or Platelet count &lt;75 x 10^9/L, or Hemoglobin&lt;90g/L&#xD;
&#xD;
          -  Cr &gt;1.5×ULN&#xD;
&#xD;
          -  Other malignancy within the past 5 years except for adequately treated carcinoma in&#xD;
             situ of the cervix or cutaneous basal cell carcinoma&#xD;
&#xD;
          -  Known brain metastasis, spinal cord compression, carcinomatous meningitis, or cerebral&#xD;
             or soft meningeal disease through CT or MRI during screening stage&#xD;
&#xD;
          -  Within the past 5 years, subjects have one of the following disease: myocardial&#xD;
             infarction, serious/instable angina pectoris, symptomatic congestive heart failure or&#xD;
             cerebrovascular accident from coronary/peripheral artery bypass grafting&#xD;
&#xD;
          -  Known human immunodeficiency virus positivity&#xD;
&#xD;
          -  Joining in other trail&#xD;
&#xD;
          -  Women who are pregnant or lactating; No contraception for subject during childbearing&#xD;
             period&#xD;
&#xD;
          -  Subject with other serious acute and chronic physical or mental problems, or&#xD;
             laboratory abnormality, will increase the risks associated with trail or drug. It will&#xD;
             also interference the judgment of the results. In the judgment of the investigator,&#xD;
             subject is inadequate to participant the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Jian</last_name>
    <phone>008613601310849</phone>
    <email>oncogene@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Jian</last_name>
      <phone>008613601310849</phone>
      <email>oncogene@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Xin</last_name>
      <phone>008613683285233</phone>
    </contact>
    <investigator>
      <last_name>Wu Xin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Xinhua</last_name>
      <phone>008613828463644</phone>
    </contact>
    <investigator>
      <last_name>Zhang Xinhua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No.81 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liu Xiufeng</last_name>
      <phone>008613357837170</phone>
    </contact>
    <investigator>
      <last_name>Liu Xiufeng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou Ye</last_name>
      <phone>008613661736873</phone>
    </contact>
    <investigator>
      <last_name>Zhou Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang Xiaobo</last_name>
    </contact>
    <investigator>
      <last_name>Liang Xiaobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital , Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhang Bo</last_name>
      <phone>008613881952600</phone>
    </contact>
    <investigator>
      <last_name>Zhang Bo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD，PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

